Cerebral Tissue Oxygenation in Highlanders/Lowlanders

Cerebral Tissue Oxygenation in Highlanders With Pulmonary Hypertension Compared to Highlanders Without Pulmonary Hypertension and Lowlanders

NCT03172429•University of Zurich

View on ClinicalTrials.gov

Summary

The purpose of the current study is to evaluate the cerebral tissue oxygenation of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.

Eligibility

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•high altitude pulmonary hypertension confirmed by clinical presentation and mean pulmonary artery pressure \>30 mmHg measured by echocardiography at altitude of residence.
•healthy subjects (high altitude controls)
•Both genders
•Age \>16 y
•Kyrgyz ethnicity
•born, raised and currently living at \>2500 m
•healthy subjects currently living at \<1000 m (low altitude controls)

Exclusion Criteria

•Pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography
•Excessive erythrocytosis
•Other coexistent disorders that may interfere with the cardio-respiratory system and sleep
•Regular use of medication that affects control of breathing
•Heavy smoking

Locations (1)

National Center for Cardiology and Internal Medicine

Bishkek, Kyrgyzstan

Key Dates

Start Date

May 24, 2017

Primary Completion Date

August 16, 2017

Completion Date

August 16, 2017

Last Updated

August 16, 2019

Enrollment

ACTUAL participants

Conditions

High Altitude Pulmonary Hypertension

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

NCT06489704

High Altitude Pulmonary Hypertension

View study

NOT_YET_RECRUITING

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

NCT06489730

High Altitude Pulmonary HypertensionSleep Apnea

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 16, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cerebral Tissue Oxygenation in Highlanders/Lowlanders

Inclusion Criteria

Exclusion Criteria

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers